Observational studyScientific reports2025
Association of ventricular arrhythmias with lamotrigine: an observational cohort study.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and Validation of a Model to Predict Secondary Arrhythmia in Patients With Epilepsy.CNS neuroscience & therapeutics · 2025Article
- Association of ventricular arrhythmias with lamotrigine: an observational cohort study.Scientific reports · 2025Observational
- Cardiac Electrophysiological Effects of the Sodium Channel-Blocking Antiepileptic Drugs Lamotrigine and Lacosamide.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Whether lamotrigine (LTG) is associated with ventricular tachycardia (VT) in bipolar disorder (BPD), partial seizures (PSZ) and generalized tonic-clonic seizures (GTSZ) with and without structural heart disease (SHD) remains controversial leading to a real-world comparative cohort observational study. A retrospective observational comparative safety study was performed using a large healthcare claims database of adult participants, analyzing the risk of VT incidence. Patients diagnosed with BPD, PSZ or GTSZ where free from supraventricular (SVT) or VT during the 6-month baseline period. Exposure to LTG versus commonly prescribed alternative agents was the CTR. One-year cumulative VT incidence was calculated for GTSZ, PSZ and BPD using Kaplan-Meier estimator adjusted for baseline characteristics. The analytic cohort included 153,852 LTG and 213,593 CTR for BPD, 10,275 LTG and 24,971 CTR for PSZ, and 5,860 LTG and 17,506 CTR for GTSZ. The 1-year VT cumulative incidence from LTG or CTR free from was 0.79% vs. 0.68% in BPD, 0.76% vs. 0.58% in PSZ, and 0.93% vs. 0.40% in GTSZ cohorts, The adjusted HR [95% CI] estimates were 1.326 [1.122-1.568, p < 0.01], 1.403 [0.920-2.138, p = 0.11], and 1.180 [0.607-2.295, p = 0.63]. In adult participants with BPD, LTG has a statistically significant association to increase VT risk compared to commonly prescribed alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.